Our top pick for
Biofrontera AG is a pharmaceuticals business based in the US. Biofrontera shares (BFRA) are listed on the NASDAQ and all prices are listed in US Dollars. Biofrontera employs 149 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$1.94|
|52-week range||$1.50 - $6.89|
|50-day moving average||$2.89|
|200-day moving average||$4.65|
|Wall St. target price||$8.50|
|Dividend yield||$0 (0%)|
|Earnings per share (TTM)||$-0.61|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2022-06-25)||N/A|
|1 month (2022-06-02)||N/A|
|3 months (2022-04-06)||-15.65%|
|6 months (2022-01-06)||-36.81%|
|1 year (2021-07-06)||-69.69%|
|2 years (2020-07-06)||-70.87%|
|3 years (2019-07-03)||18.22|
|5 years (2017-07-02)||N/A|
Valuing Biofrontera stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Biofrontera's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Biofrontera's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $1.5 million.
The EBITDA is a measure of a Biofrontera's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||$28 million|
|Gross profit TTM||$26.8 million|
|Return on assets TTM||-10.51%|
|Return on equity TTM||-124.08%|
|Market capitalisation||$75.7 million|
TTM: trailing 12 months
We're not expecting Biofrontera to pay a dividend over the next 12 months.
Over the last 12 months, Biofrontera's shares have ranged in value from as little as $1.5 up to $6.89. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Biofrontera's is 1.548. This would suggest that Biofrontera's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.
Everything we know about the Warrantee IPO, plus information on how to buy in.
Everything we know about the Treasure Global IPO, plus information on how to buy in.
Everything we know about the BIOLIFE4D IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.